TrialLancet (London, England)2021

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Maheshi N Ramasamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.